Tscan Therapeutics is trading at $0.19 (-7.73%); no clear company-specific explanation for the October 26 decline was found. - A proxy filing appeared in search results, but no source linked it to the move. - The September reorganization, workforce reduction, and pause in the Phase 3 ALLOHA-2 trial are prior context, not confirmed catalysts for this session. - Major U.S. indexes were higher, so broad-market weakness does not explain the decline.